Category Lead Oncology & Rare Disease - Middle East

ROLE SUMMARY The Category Lead, Oncology & Rare Disease – Middle East is a strategic member of the Middle East Leadership Team, accountable for the portfolio’s end-to-end strategy, performance and long-term value across the cluster. The role translates enterprise and regional priorities into differentiated portfolio, launch and market strategies that balance near-term performance with sustainable growth and patient impact. It sets clear priorities across in-line brands, Growth Knots and breakthrough launches, enabling disciplined investment, resource allocation and execution across diverse Middle East healthcare systems. Working across Commercial, Medical, Access & Value, Regulatory, Policy & Public Affairs, Supply, Finance, Legal and Compliance—as well as regional and global teams—the role creates the conditions for launch excellence, expanded patient access and sustainable portfolio growth. It also builds a high-performing marketing organization and strengthens category leadership, customer engagement and execution capabilities across the cluster. CORE ACCOUNTABILITIES 1. CATEGORY STRATEGY & PORTFOLIO LEADERSHIP • Translate the Middle East Oncology and Rare Disease strategy into clear portfolio, brand, market and customer priorities aligned with the cluster operating plan and growth agenda. • Lead end-to-end portfolio planning across in-line brands, new indications, pipeline assets and future launches, balancing current performance with long-term category value. • Shape differentiated strategies that reflect local disease burden, clinical pathways, diagnostic requirements, patient needs, access conditions and competitive dynamics. • Establish category governance, operating rhythms and performance reviews that connect enterprise and regional strategy with market execution. • Make disciplined portfolio trade-offs and direct resources toward the highest-value opportunities for patients and the business. 2. BUSINESS & P&L LEADERSHIP • Own category performance, providing clear direction on revenue, profitability, market share, investment and resource deployment. • Lead annual operating and long-range planning for the Oncology and Rare Disease portfolio, ensuring robust assumptions, scenarios, risk assessment and growth choices. • Prioritize approved marketing and commercial investments across brands, launches and markets, reallocating resources to the highest-impact opportunities. • Monitor performance and intervene early when launch, demand, access, supply or execution risks threaten category objectives. • Use performance data, market intelligence and customer insights to accelerate decisions and strengthen execution. 3. LAUNCH & LIFECYCLE EXCELLENCE • Lead integrated launch strategy and readiness for new products, indications and presentations across Middle East markets. • Define launch ambition, sequencing, market archetypes, customer strategy, investment requirements and critical success factors. • Build integrated launch plans across Regulatory, Medical, Access & Value, Policy & Public Affairs, Supply, Marketing, Sales and customer engagement. • Track readiness and post-launch performance through clear milestones and governance, accelerating decisions and removing execution barriers. • Optimize lifecycle strategies for in-line assets to sustain growth, expand patient reach and maximize portfolio value. 4. PATIENT JOURNEY, DIAGNOSTICS & ECOSYSTEM DEVELOPMENT • Identify barriers across awareness, diagnosis, referral, treatment initiation, monitoring and continuity of care. • Translate patient and healthcare-system insights into compliant, cross-functional priorities and solutions. • Sponsor initiatives that strengthen diagnostic pathways, specialist networks and coordinated care. • Ensure category strategies